These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 34554438)

  • 1. Anifrolumab: First Approval.
    Deeks ED
    Drugs; 2021 Oct; 81(15):1795-1802. PubMed ID: 34554438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trial of Anifrolumab in Active Systemic Lupus Erythematosus.
    Morand EF; Furie R; Tanaka Y; Bruce IN; Askanase AD; Richez C; Bae SC; Brohawn PZ; Pineda L; Berglind A; Tummala R;
    N Engl J Med; 2020 Jan; 382(3):211-221. PubMed ID: 31851795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacological actions of anifrolumab (Saphnelo
    Ueha T; Kusuda M; Shibata S; Hirata M; Ozaki N
    Nihon Yakurigaku Zasshi; 2022; 157(4):271-279. PubMed ID: 35781459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials.
    Tanaka Y; Tummala R
    Mod Rheumatol; 2021 Jan; 31(1):1-12. PubMed ID: 32814461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study.
    Tanaka Y; Takeuchi T; Okada M; Ishii T; Nakajima H; Kawai S; Nagashima T; Hayashi N; Wang L; Tummala R
    Mod Rheumatol; 2020 Jan; 30(1):101-108. PubMed ID: 30793642
    [No Abstract]   [Full Text] [Related]  

  • 6. Anifrolumab in systemic lupus erythematosus: current knowledge and future considerations.
    Anderson E; Furie R
    Immunotherapy; 2020 Apr; 12(5):275-286. PubMed ID: 32237942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review.
    Liu Z; Cheng R; Liu Y
    Front Immunol; 2022; 13():996662. PubMed ID: 36211347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anifrolumab: first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus.
    Gensous N; Lazaro E; Blanco P; Richez C
    Expert Rev Clin Immunol; 2024; 20(1):21-30. PubMed ID: 37800604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials.
    Baker T; Sharifian H; Newcombe PJ; Gavin PG; Lazarus MN; Ramaswamy M; White WI; Ferrari N; Muthas D; Tummala R; Morand EF; Furie RA; Vital EM; Chamberlain C; Platt A; Al-Mossawi H; Brohawn PZ; Csomor E
    Ann Rheum Dis; 2024 Jul; 83(8):1018-1027. PubMed ID: 38569851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.
    Furie R; Khamashta M; Merrill JT; Werth VP; Kalunian K; Brohawn P; Illei GG; Drappa J; Wang L; Yoo S;
    Arthritis Rheumatol; 2017 Feb; 69(2):376-386. PubMed ID: 28130918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date.
    Felten R; Scher F; Sagez F; Chasset F; Arnaud L
    Drug Des Devel Ther; 2019; 13():1535-1543. PubMed ID: 31190735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab.
    Tang W; Tummala R; Almquist J; Hwang M; White WI; Boulton DW; MacDonald A
    Clin Pharmacokinet; 2023 May; 62(5):655-671. PubMed ID: 37148484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis.
    Jayne D; Rovin B; Mysler EF; Furie RA; Houssiau FA; Trasieva T; Knagenhjelm J; Schwetje E; Chia YL; Tummala R; Lindholm C
    Ann Rheum Dis; 2022 Apr; 81(4):496-506. PubMed ID: 35144924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anifrolumab in systemic lupus erythematosus.
    Loncharich MF; Robertson I
    Drugs Today (Barc); 2023 Feb; 59(2):53-61. PubMed ID: 36811405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evaluation of anifrolumab for use in adults with systemic lupus erythematosus.
    Ahmed AA; Osman N; Furie R
    Expert Rev Clin Immunol; 2022 Nov; 18(11):1095-1106. PubMed ID: 36083692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials.
    Bruce IN; van Vollenhoven RF; Psachoulia K; Lindholm C; Maho E; Tummala R
    Lupus Sci Med; 2023 Jan; 10(1):. PubMed ID: 36639192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials.
    Tummala R; Abreu G; Pineda L; Michaels MA; Kalyani RN; Furie RA; Morand EF
    Lupus Sci Med; 2021 Feb; 8(1):. PubMed ID: 33597205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anifrolumab (Saphnelo) for systemic lupus erythematosus.
    Med Lett Drugs Ther; 2021 Sep; 63(1633):146-147. PubMed ID: 34550961
    [No Abstract]   [Full Text] [Related]  

  • 19. Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice.
    Tanaka Y
    RMD Open; 2023 Aug; 9(3):. PubMed ID: 37597847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised, parallel-group, double-blind, placebo-controlled phase 3 study to Determine the effectiveness of the type I interferon receptor antibody, Anifrolumab, In SYstemic sclerosis: DAISY study design and rationale.
    Khanna D; Denton CP; Assassi S; Kuwana M; Allanore Y; Domsic RT; Kleoudis C; Xu J; Csomor E; Seo C; Albulescu M; Tummala R; Al-Mossawi H; Kalyani RN; Del Galdo F
    Clin Exp Rheumatol; 2024 Aug; 42(8):1635-1644. PubMed ID: 39152751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.